Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: A phase I study

British Journal of Haematology

Volumn 162, Issue 5, 2013, Pages 693-701

  Liebman, Howard A ^a   Saleh, Mansoor N ^b   Bussel, James B ^c   Negrea, Ovidiu George ^d   Horne, Heather ^e   Wegener, William A ^e   Goldenberg, David M ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Georgia Cancer Specialists   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Low Country Cancer Care Associates   (United States)

^e IMMUNOMEDICS INC   (United States)

Author keywords

Antibody; CD20; HA20; Immune thrombocytopenia; ITP; Subcutaneous therapy

Indexed keywords

IMMUNOGLOBULIN; STEROID; VELTUZUMAB;

ADULT; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; INFECTION; INFUSION RELATED REACTION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROAT DISEASE; THROMBOCYTE COUNT;

EID: 84881662563     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12448     Document Type: Article

References (33)

1. Arnold, D.M., Dentali, F., Crowther, M.A., Meyer, R.M., Cook, R.J., Sigouin, C., Fraser, G.A., Lim, W. & Kelton, J.G. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 146, 25-33.
2. Azinovic, I., DeNardo, G.L., Lamborn, K.R., Mirick, G., Goldstein, D., Bradt, B.M. & DeNardo, S.J. (2006) Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunology and Immunotherapy, 55, 1451-1458.
3. Bartelds, G.M., Krieckaert, C.L., Nurmohamed, M.T., van Schouwenburg, P.A., Lems, W.F., Twisk, J.W., Dijkmans, B.A., Aarden, L. & Wolbink, G.J. (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. The Journal of the American Medical Association, 305, 1460-1468.
4. Braendstrup, P., Bjerrum, O.W., Nielsen, O.J., Jensen, B.A., Clausen, N.T., Hansen, P.B., Andersen, I., Schmidt, K., Andersen, T.M., Peterslund, N.A., Birgens, H.S., Plesner, T., Pedersen, B.B. & Hasselbalch, H.C. (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology, 78, 275-280.
5. British Committee for Standards in Haematology General Haematology Task Force. (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. British Journal of Haematology, 120, 574-596.
6. Brown, E.G., Wood, L. & Wood, S. (1999) The medical dictionary for regulatory activities (MedDRA). Drug Safety, 20, 109-117.
7. Bussel, J.B., Kuter, D.J., George, J.N., McMillan, R., Aledort, L.M., Conklin, G.T., Lichtin, A.E., Lyons, R.M., Nieva, J., Wasser, J.S., Wiznitzer, I., Kelly, R., Chen, C.F. & Nichol, J.L. (2006) AMG 531, a thrombopoesis-stimulating protein, for chronic ITP. The New England Journal of Medicine, 355, 1672-1681.
8. Bussel, J.B., Cheng, G., Saleh, M.N., Psaila, B., Kovaleva, L., Meddeb, B., Kloczko, J., Hassani, H., Mayer, B., Stone, N.L., Arning, M., Provan, D. & Jenkins, J.M. (2007) Eltrombopaq for the treatment of chronic idiopathic thrombocytopenic purpura. The New England Journal of Medicine, 357, 2237-2247.
9. Cines, D.B. & Bussel, J.B. (2005) How I treat thrombocytopenic purpura (ITP). Blood, 106, 2244-2251.
10. Cooper, N., Stasi, R., Cunningham-Rundles, S., Feuerstein, M.A., Leonard, J.P., Amadori, S. & Bussel, J.B. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 125, 232-239.
11. Elstrom, R., Ghanima, W., Lee, S.Y., Turenne, I. & Bussel, J.B. (2011) Standard dose rituximab plus 2-4 cycles of pulse dexamethasone is effective and tolerable in treatment of immune thrombocytopenia (ITP). Blood, 118, 527 (abstract 1166).
12. Genovese, M.C., Kaine, J.L., Lowenstein, M.B., Del Giudice, J., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R.G., Sweiss, N.J., Spaniolo, G. & Dummer, W.; ACTION Study Group. (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis & Rheumatism, 58, 2652-2661.
13. George, J.N., Woolf, S.H., Raskob, G.E., Wasser, J.S., Aledort, L.M., Ballem, P.J., Blanchette, V.S., Bussel, J.B., Cines, D.B., Kelton, J.G., Lichtin, A.E., McMillan, R., Okerbloom, J.A., Regan, D.H. & Warrier, I. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood, 88, 3-40.
14. Godeau, B., Porcher, R., Fain, O., Lefrère, F., Fenaux, P., Cheze, S., Vekhoff, A., Chauveheid, M.P., Stirnemann, J., Galicier, L., Bourgeois, E., Haiat, S., Varet, B., Leporrier, M., Papo, T., Khellaf, M., Michel, M. & Bierling, P. (2008) Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura - results of a prospective multicenter phase 2 study. Blood, 112, 999-1004.
15. Goldenberg, D.M., Rossi, E.A., Stein, R., Cardillo, T.M., Czuczman, S. & Hernandez-Ilizaliturri, F.J. (2009) Properties and structure-function relationship of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood, 113, 1062-1070.
16. Goldenberg, D.M., Morschhauser, F. & Wegener, W.A. (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leukemia & Lymphoma, 51, 747-755.
17. Gudbrandsdottir, S., Birgens, H.S., Jensen, B.A., Jensen, M.K., Kjeldsen, L., Klausen, T.W., Larsen, H., Mourits-Andersen, H.T., Nielsen, C.H., Nielsen, O.J., Plesner, T., Pulczynski, S., Rasmussen, I.H., Rønnov-Jessen, D. & Hasselbalch, H.C. (2013) Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood, 121, 1976-1981.
18. Hasan, A., Michel, M., Patel, V., Stasi, R., Cunningham-Rundles, S., Leonard, J. & Bussel, J. (2009) Repeated courses of rituximab in chronic ITP: three different regimens. American Journal of Hematology, 84, 661-665.
19. Kuter, D.J., Bussel, J.B., Lyons, R.M., Pullarkat, V., Gernsheimer, T.B., Senecal, F.M., Aledort, L.M., George, J.N., Kessler, C.M., Sanz, M.A., Liebman, H.A., Slovick, F.T., de Wolf, J.T., Bourgeois, E., Guthrie, T.H. Jr, Newland, A., Wasser, J.S., Hamburg, S.I., Grande, C., Lefrère, F., Lichtin, A.E., Tarantino, M.D., Terebelo, H.R., Viallard, J.F., Cuevas, F.J., Go, R.S., Henry, D.H., Redner, R.L., Rice, L., Schipperus, M.R., Guo, D.M. & Nichol, J.L. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet, 371, 395-403.
20. Medeot, M., Zaja, F., Vianelli, N., Battista, M., Baccarani, M., Patriarca, F., Soldano, F., Isola, M., De Luca, S. & Fanin, R. (2008) Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow up results. European Journal of Haematology, 81, 165-169.
21. Miotti, S., Negri, D.R., Valota, O., Calabrese, M., Bolhuis, R.L., Gratama, J.W., Colnaghi, M.I. & Canevari, S. (1999) Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. International Journal of Cancer, 84, 62-68.
22. Morschhauser, F., Leonard, J.P., Fayad, L., Coiffier, B., Petillon, M.O., Coleman, M., Schuster, S.J., Dyer, M.J., Horne, H., Teoh, N., Wegener, W.A. & Goldenberg, D.M. (2009) Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of Clinical Oncology, 27, 3346-3353.
23. Negrea, G.O., Elstrom, R., Allen, S.L., Rai, K.R., Abbasi, R.M., Farber, C.M., Teoh, N., Horne, H., Wegener, W.A. & Goldenberg, D.M. (2011) Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica, 96, 567-573.
24. Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L. Jr & Crowther, M.A. (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 117, 4190-4207.
25. Newland, A., Cauolier, M.T., Kappers-Klunne, M., Schipperus, M.R., Lefrere, F., Zwaginga, J.J., Christal, J., Chen, C.F. & Nichol, J.L. (2006) An open-label, unit dose-finding study of AMG 531, a novel thrombopoesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. British Journal of Haematology, 135, 547-553.
26. Page, L., Psaila, B., Provan, D., Hamilton, J.M., Jenkins, J.M., Elish, A.S., Lesser, M.L. & Bussel, J.B. (2007) The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. British Journal of Haematology, 138, 245-248.
27. Patel, V.L., Mahévas, M., Lee, S.Y., Stasi, R., Cunningham-Rundles, S., Godeau, B., Kanter, J., Neufeld, E., Taube, T., Ramenghi, U., Shenoy, S., Ward, M.J., Mihatov, N., Patel, V.L., Bierling, P., Lesser, M., Cooper, N. & Bussel, J.B. (2012) Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, 119, 5989-5995.
28. Peñalver, F.J., Jiménez-Yuste, V., Almagro, M., Alvarez-Larrán, A., Rodríguez, L., Casado, M., Gallur, L., Giraldo, P., Hernández, R., Menor, D., Rodríguez, M.J., Caballero, D., González, R., Mayans, J., Millán, I. & Cabrera, J.R. (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Annals of Hematology, 85, 400-406.
29. Provan, D., Stasi, R., Newland, A.C., Blanchette, V.S., Bolton-Maggs, P., Bussel, J.B., Chong, B.H., Cines, D.B., Gernsheimer, T.B., Godeau, B., Grainger, J., Greer, I., Hunt, B.J., Imbach, P.A., Lyons, G., McMillan, R., Rodeghiero, F., Sanz, M.A., Tarantino, M., Watson, S., Young, J. & Kuter, D.J. (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 115, 168-186.
30. Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., Bussel, J.B., Cines, D.B., Chong, B.H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M.G., McMillan, R., Sanz, M.A., Imbach, P., Blanchette, V., Kühne, T., Ruggeri, M. & George, J.N. (2009) Standardization of terminology, definitions, and outcome in idiopathic thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood, 113, 2386-2393.
31. Stein, R., Qu, Z., Chen, S., Rosario, A., Shi, V., Hayes, M., Horak, I.D., Hansen, H.J. & Goldenberg, D.M. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clinical Cancer Research, 10, 2868-2878.
32. Tahir, H., Bhatia, A., Wegener, W.A. & Isenberg, D.A. (2005) Humanised anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibody against rituximab. Rheumatology, 44, 561-562.
33. Zaja, F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Zaccaria, A., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., Campagna, S., Ferrara, F., Angelucci, E., Usala, E., Cantoni, S., Visani, G., Fornaro, A., Rizzi, R., De Stefano, V., Casulli, F., Battista, M.L., Isola, M., Soldano, F., Gamba, E. & Fanin, R. (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood, 115, 2755-2762.